Performance Status — Functional Well-Being Scale

Performance status represents an objective assessment of an individual's functional reserve, ambulatory status, and degree of self-care. It reflects the overall physiological toll imposed by malignancy and underlying co-morbidities, providing prognostic insight distinct from chronological age or anatomical stage of disease.

Clinicians primarily record this assessment using validated scoring instruments, most notably the Eastern Cooperative Oncology Group (ECOG) scale (ranging from 0 for fully active to 5 for deceased) or the Karnofsky Performance Scale (KPS, running from 100% down to 0%).

Performance status is one of the most critical factors guiding treatment decisions. Intensive interventions like aggressive multi-agent chemotherapy, extensive surgery, or concurrent chemoradiation demand substantial physiological resilience. If functional capacity is significantly reduced, the risk of severe toxicity may outweigh therapeutic benefit. Knowing this score helps clinicians tailor chemotherapy dosages, select gentler treatment modalities, prioritise supportive care, and determine eligibility for clinical research protocols.

This metric does not involve laboratory blood tests or imaging. Instead, it is assessed during a clinical consultation through direct medical observation, structured physical examination, and detailed patient-reported functional questionnaires. Clinicians assign an ECOG grade (0 to 4) or Karnofsky percentage based on mobility, work capacity, and the proportion of waking hours spent resting in bed or a chair.

Performance status is evaluated in every cancer type, including solid tumours like lung, colorectal, breast, and prostate cancer, as well as haematological malignancies like leukaemia, lymphoma, and multiple myeloma. It is routinely recalculated at diagnosis, prior to each treatment cycle, and when evaluating disease progression across all oncological settings.

A good performance status (ECOG 0–1) generally qualifies patients for standard curative-intent or intensive systemic therapies. A compromised score (ECOG 2) often prompts dose modifications or single-agent regimens to avoid excessive toxicity. For individuals with poor performance status (ECOG 3–4), systemic chemotherapy is often avoided due to high complication rates, prompting a shift toward palliative radiotherapy, targeted options with favourable toxicity, or dedicated symptom management.